Working… Menu
Trial record 9 of 19 for:    "Hypogonadism" | "Calcium, Dietary"

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01532414
Recruitment Status : Completed
First Posted : February 14, 2012
Results First Posted : May 27, 2015
Last Update Posted : May 27, 2015
Information provided by (Responsible Party):
Repros Therapeutics Inc.

Brief Summary:
The purpose of ZA-301 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T<300 ng/dL) and normal sperm concentration, compared to changes with placebo. Subjects must not have previously been treated with testosterone products within the last 6 months.

Condition or disease Intervention/treatment Phase
Secondary Hypogonadism Drug: Androxal Drug: Placebo Phase 3

Detailed Description:

Protocol ZA-301 is a randomized, double-blind, placebo-controlled multi-center Phase 3 study to evaluate normalization of morning testosterone levels in overweight men with acquired hypogonadotropic hypogonadism and normal baseline sperm concentrations. The study requires 10 to 12 clinic visits (2 for eye exams), and is approximately 4 to 5½ months in duration. Subjects will be treated for 12-18 weeks. At Visit 3 (Week 6) subjects who do not achieve morning T values ≥300 ng/dL will be up-titrated to 25 mg. Placebo subjects may be sham titrated. Up-titrated subjects will receive an additional 6 weeks of treatment (18 weeks total). A schedule of procedures and assessments is displayed in Section 4. The study will enroll up to 152 male subjects, up to 114 randomized to treatment with Androxal and up to 38 randomized to placebo, in a 3:1 ratio. Subjects must not have used any prior testosterone treatments within the last 6 months.

Eligible subjects must have 2 consecutive assessments of morning T below 300 ng/dL and LH below 9.4 mIU/mL. They will provide 2 sperm samples at baseline, at least 2 days apart, another 2 after 12 weeks of treatment, and up-titrated subjects will provide an additional 2 samples at the end of treatment. After 12 weeks of treatment (V5) all subjects will undergo serial T assessment for determination of the Cavg. Safety assessments will include collection of adverse events, eye examinations, physical examinations and clinical laboratory assessments.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 151 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration
Study Start Date : August 2012
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Androxal 12.5 mg
Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
Drug: Androxal
oral, capsules, taken one time daily, for 3 months
Other Name: Enclomiphene citrate

Experimental: Androxal 25 mg
Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
Drug: Androxal
oral, capsules, taken one time daily, for 3 months
Other Name: Enclomiphene citrate

Placebo Comparator: Placebo
Placebo oral capsules taken one time daily
Drug: Placebo
Oral capsule taken one time daily for 3 months
Other Name: Dummy

Primary Outcome Measures :
  1. Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range [ Time Frame: 3 months ]

    Proportion of pooled Androxal subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment. Cavg will be calculated as the numerical average of 24-hour serial testosterone assessments at 0, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours after dosing.

    If the lower limit of the 95% confidence interval for the Androxal treatment group at Week 12 is at least 67%, then the co-primary endpoint based on the Cavg for testosterone has been achieved.

    FDA specified primary endpoint did not include comparison to placebo, thus the proportion of placebo subjects with average serum concentration (Cavg) for T in the normal range (300 - 1040 ng/dL) after 12 weeks of treatment was not calculated.

  2. Subjects With 50% or Greater Decrease in Sperm Concentration Comparison of Proportion of Subjects With 50% or Greater Decrease in Sperm [ Time Frame: 3 months ]

    Proportion of subjects with a 50% or greater decrease in sperm concentration from baseline after 12 weeks of treatment in Androxal treated subjects to placebo.

    The difference between the proportions (placebo minus Androxal) and corresponding 95% confidence interval was determined and compared to the equivalence limit of -20%. If the lower limit of the 95% confidence interval was greater than -20%, then Androxal would be concluded to be non-inferior to placebo in causing a 50% reduction in sperm concentrations.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Overweight (BMI 25 to 42 kg/m2 inclusive) males age 18 to 60 inclusive
  2. All clinical laboratory tests within normal ranges (any clinically significant deviation of laboratory results will require approval of sponsor)
  3. Previously or concurrently diagnosed as having secondary hypogonadism characterized as having 2 consecutive morning testosterone assessments < 300ng/dL, one of which must be confirmed at Baseline.
  4. LH < 9.4 mIU/mL (at Visit 1 only)
  5. Sperm count ≥ 15 million per milliliter (assessed twice at least 48 hours apart)
  6. Ability to complete the study in compliance with the protocol
  7. Ability to understand and provide written informed consent
  8. Agreement to provide a total of up to 6 semen sample in a sponsor-approved clinic on up to 6 separate occasions.

Exclusion Criteria:

  1. Any prior use of testosterone treatments within the last 6 months
  2. Use of spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone products during the study
  3. Use of Clomid in the past year
  4. Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes will be allowed into the study. Newly diagnosed diabetics need to be treated for at least 48 hours before being enrolled in the study.
  5. Clinically significant abnormal findings at Screening (Visit 1) or Baseline, based on the Investigator's assessment
  6. A hematocrit >54% or a hemoglobin >17 g/dL (sponsor may approve enrollment of subjects with hemoglobin up to 17.5 g/dL if the subject is at a location with a high elevation)
  7. Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.
  8. Known hypersensitivity to Clomid
  9. Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade > 2 based on 0-4 scale or any trace of posterior subcapsular cataract)
  10. Abnormal fundoscopy exam such as central retinal vein occlusion
  11. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study
  12. Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome, primary hypogonadism, vasectomy, or tumors of the pituitary)
  13. Current or history of breast cancer
  14. Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a PSA>3.6
  15. Presence or history of known hyperprolactinemia with or without a tumor
  16. Chronic use of medications such as glucocorticoids
  17. History of drug abuse or chronic narcotic use including methadone
  18. A recent history of alcoholism or illegal substance or steroid abuse (<2 years) or presence of moderate alcohol use (>21 drinks per week)
  19. Subjects with known history of HIV and/or Hepatitis C
  20. Subjects with end stage renal disease
  21. History of liver disease (including malignancy) or a confirmed AST or ALT >3 times the upper limit of normal
  22. History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia or know history of QTc interval prolongation
  23. History of cerebrovascular disease
  24. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism)
  25. History of erythrocytosis or polycythemia
  26. Subjects with cystic fibrosis (mutation of the CFTR gene)
  27. Subjects unable to provide a semen sample in a sponsor-approved clinic
  28. Enrollment in a previous Androxal study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01532414

Layout table for location information
United States, Alabama
Coastal Clinical Research
Mobile, Alabama, United States, 36608
United States, Arkansas
Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States, 72205
United States, California
SC Clinical Research
Garden Grove, California, United States, 92844
Mission Internal Medicine Group
Mission Viejo, California, United States, 92691
Rancho Cucamonga Clinical Trials
Rancho Cucamonga, California, United States, 91730
San Diego Sexual Medicine
San Diego, California, United States, 92120
West Coast Clinical Research
Tarzana, California, United States, 91356
United States, Florida
Florida Fertility Institute
Clearwater, Florida, United States, 33759
Tampa Bay Medical Research
Clearwater, Florida, United States, 33761
ALL Medical Research
Cooper City, Florida, United States, 33024
Clinical Research of South Florida
Coral Gables, Florida, United States, 33134
Therafirst Medical Center
Fort Lauderdale, Florida, United States, 33308
Phase One Solutions
Miami Gardens, Florida, United States, 33169
Well Pharma Medical Research Group
Miami, Florida, United States, 33143
Meridien Research
St. Petersburg, Florida, United States, 33709
United States, Kentucky
Central Kentucky Research Associates
Lexington, Kentucky, United States, 40509
United States, Nevada
Clinical Research Advantage
Henderson, Nevada, United States, 89052
United States, New Jersey
Premier Urology Associates
Lawrenceville, New Jersey, United States, 08648
United States, New York
Rochester Clinical Research
Rochester, New York, United States, 14609
United States, South Carolina
Coastal Carolina Research Center
Mount Pleasant, South Carolina, United States, 29464
United States, Tennessee
New Orleans Center for Clinical Research
Knoxville, Tennessee, United States, 37920
United States, Utah
Lone Peak Family Medicine
Draper, Utah, United States, 84020
Granger Medical Clinic
West Valley City, Utah, United States, 84120
Sponsors and Collaborators
Repros Therapeutics Inc.
Layout table for investigator information
Study Director: Joseph S Podolski Repros Therapeutics

Additional Information:
Layout table for additonal information
Responsible Party: Repros Therapeutics Inc. Identifier: NCT01532414     History of Changes
Other Study ID Numbers: ZA-301
First Posted: February 14, 2012    Key Record Dates
Results First Posted: May 27, 2015
Last Update Posted: May 27, 2015
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Calcium Chelating Agents
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Gonadal Disorders
Endocrine System Diseases
Citric Acid
Sodium Citrate
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Estrogen Antagonists
Hormone Antagonists
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators